BusinessTherapeuticsVoyager

Voyager Therapeutics Stock Had Been Beaten Down. Here’s Why It’s Soaring.


  • Order Reprints

  • Print Article

Shares of a small biotech called Voyager Therapeutics jumped 46% on Wednesday after the company said Pfizer had licensed access to its gene therapy technology in a deal worth up to $630 million.

According to Voyager (ticker: VYGR), Pfizer will pay $30 million up front for options to use proteins known as capsids developed by Voyager in its gene therapy programs. The capsids are shells that coat the viruses used to deliver genetic material as part of gene therapy. Voyager’s technology identifies capsids designed to more effectively…


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close
Close